New treatment for lung cancer that targets mutant EGFR
Development of a first-in-class mEGFR dimerization inhibitor
This study is testing a new drug called DGD1202 to see if it can help lung cancer patients whose current treatments aren't working anymore by targeting a specific protein that contributes to their cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11080399 on NIH RePORTER |
What this research studies
This research focuses on developing a novel drug, DGD1202, that inhibits the dimerization of the mutant epidermal growth factor receptor (mtEGFR), which is often responsible for lung cancer. Current treatments, such as EGFR tyrosine kinase inhibitors, become ineffective after a short period due to resistance, leaving patients with limited options. The study aims to evaluate the effectiveness of DGD1202 in killing TKI-resistant lung cancer cells and in animal models derived from lung cancer patients. By inducing degradation of the mtEGFR protein, this approach seeks to provide a new therapeutic option for patients who have not responded to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients with mutant EGFR who have previously been treated with tyrosine kinase inhibitors and are experiencing resistance.
Not a fit: Patients without mutant EGFR or those who have not undergone treatment with tyrosine kinase inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new treatment option for lung cancer patients who have developed resistance to current therapies.
How similar studies have performed: While the approach of targeting EGFR dimerization is novel, previous research has shown promise in targeting mutant EGFR in other contexts, indicating potential for success.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Nyati, Mukesh K. — University of Michigan at Ann Arbor
- Study coordinator: Nyati, Mukesh K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.